Abstract:Adapting the final sample size of a trial to the evidence accruing during the trial is a natural way to address planning uncertainty. Designs with adaptive sample size need to account for their optional stopping to guarantee strict type-I error-rate control. A variety of different methods to maintain type-I error-rate control after unplanned changes of the initial sample size have been proposed in the literature. This makes interim analyses for the purpose of sample size recalculation feasible in a regulatory context. Since the sample size is usually determined via an argument based on the power of the trial, an interim analysis raises the question of how the final sample size should be determined conditional on the accrued information. Conditional power is a concept often put forward in this context. Since it depends on the unknown effect size, we take a strict estimation perspective and compare assumed conditional power, observed conditional power, and predictive power with respect to their properties as estimators of the unknown conditional power. We then demonstrate that pre-planning an interim analysis using methodology for unplanned interim analyses is ineffective and naturally leads to the concept of optimal two-stage designs. We conclude that unplanned design adaptations should only be conducted as reaction to trial-external new evidence, operational needs to violate the originally chosen design, or post hoc changes in the objective criterion. Finally, we show that commonly discussed sample size recalculation rules can lead to paradoxical outcomes and propose two alternative ways of reacting to newly emerging trial-external evidence.

The Conditional Power of Interim Analysis and Sample Size Re-estimation

Conditional Power and Friends: The Why and How of (Un)planned, Unblinded Sample Size Recalculations in Confirmatory Trials

Sample size re-estimation in a superiority clinical trial using a hybrid classical and Bayesian procedure

The Sample Size Re-estimation of Combining CP Method and EM Algorithm

Sample Size Reestimation in Stochastic Curtailment Tests With Time‐to‐Events Outcome in the Case of Nonproportional Hazards Utilizing Two Weibull Distributions With Unknown Shape Parameters

Sample size reestimation and Bayesian predictive probability for single-arm clinical trials with a time-to-event endpoint using Weibull distribution with unknown shape parameter

A Bayesian Design for Phase II Clinical Trials with Delayed Responses Based on Multiple Imputation.

Extension of a conditional performance score for sample size recalculation rules to the setting of binary endpoints

Design and monitoring of clinical trials with an interim analysis and a negative binomial endpoint

Sample size recalculation in three-stage clinical trials and its evaluation

Estimating the Sampling Distribution of Posterior Decision Summaries in Bayesian Clinical Trials

Changing interim monitoring in response to internal clinical trial data

Sample Size Re-Estimation Without Un-Blinding for Time-to-event Outcomes in Oncology Clinical Trials

Simplification or simulation: Power calculation in clinical trials

Stochastic curtailment tests for phase II trial with time-to-event outcome using the concept of relative time in the case of non-proportional hazards

Adaptive sample size re-estimation in MRMC studies

Blinded sample size re-estimation in three-arm trials with 'gold standard' design

A Sample Size Planning Approach That Considers Both Statistical Significance and Clinical Significance

Sample size estimation for survival analysis in single-arm trials

A hybrid approach to sample size re‐estimation in cluster randomized trials with continuous outcomes

Power and Sample Size for Dose-Finding Studies with Survival Endpoints under Model Uncertainty.